Sugammadex and Decreased Time to Extubation

PHASE4CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

May 13, 2017

Primary Completion Date

October 1, 2020

Study Completion Date

October 10, 2020

Conditions
Coronary Artery Bypass Graft and/or Aortic Valve Replacement Surgery
Interventions
DRUG

Sugammadex

The administration of the study and placebo compounds will be performed by CTICU nurses who will receive the drugs in a blinded fashion from the departmental research pharmacy.

OTHER

Placebo

The administration of the study and placebo compounds will be performed by CTICU nurses who will receive the drugs in a blinded fashion from the departmental research pharmacy.

Trial Locations (1)

06510

Yale University, New Haven

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Yale University

OTHER

NCT03196167 - Sugammadex and Decreased Time to Extubation | Biotech Hunter | Biotech Hunter